National Resilience and AstraZeneca announced that the companies will establish a long-term biomanufacturing relationship in support of AstraZeneca’s portfolio. Under the agreement, AstraZeneca will have strategic access to Resilience’s end-to-end capabilities. Resilience will purchase AstraZeneca’s manufacturing facility located in West Chester, Ohio and will manufacture select AstraZeneca medicines at the facility as part of a multi-year supply agreement. The companies anticipate completing the transaction in early 2023, subject to receipt of regulatory approvals and the satisfaction of other customary closing conditions. Upon closing, Resilience will acquire the West Chester site’s operations and physical assets, retain the site’s leadership and employees, and continue to invest in the workforce and facility. The West Chester site is a commercial-scale, 580,000 square-foot facility with a strong record of regulatory and commercial drug supply performance in numerous global markets. The site is equipped with end-to-end drug product manufacturing capabilities, including aseptic filling, inspection, packaging, labeling, and cold-chain operations for vials, cartridges, pre-filled syringes, and autoinjectors, as well as a virtual reality training center.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca to acquire Neogene Therapeutics for $320M
- Merck, AstraZeneca announce EMA’s CHMP adopted positive opinion of LYNPARZA
- AstraZeneca Lynparza+biraterone recommended for E.U. approval in mCRPC
- AstraZeneca’s Imfinzi + chemotherapy recommended for approval in BTC
- AstraZeneca, Daiichi Sankyo announce Enhertu recommended for EU approval